Bolt Bio & NewAmsterdam Get Buy Ratings from H.C. Wainwright
H.C. Wainwright initiates coverage on Bolt Biotherapeutics and NewAmsterdam Pharma with Buy ratings, highlighting innovative treatments in development.
/ 1679 items
#XY↓
Olema Stock Crashes on Roche's Shadow, Not Its Own Data
Despite positive palazestrant (OP-1250) trial results, Olema Pharmaceuticals' shares dropped Monday, overshadowed by disappointing outcomes from a Roche breast cancer study.
Replimune Gets FDA Nod for RP1 Drug Resubmission
Replimune's RP1 melanoma treatment gets FDA acceptance for BLA resubmission with April 2026 review date. Wedbush upgrades stock to Outperform with $18 target as approval odds improve.
Cogent Biosciences Receives FDA Breakthrough Designation for Mastocytosis Treatment
Cogent Biosciences announces FDA Breakthrough Therapy Designation for bezuclastinib, a promising treatment for NonAdvanced Systemic Mastocytosis with NDA submission planned by year-end 2025.
Ideaya Biosciences Stock Jumps on Promising Eye Cancer Treatment Results
Ideaya Biosciences shares rise after reporting breakthrough survival data for rare eye cancer treatment combining darovasertib with Pfizer's Xalkori in clinical trial.
Canaccord Launches Tempus AI Coverage with $110 Price Target
Canaccord initiates Tempus AI with Buy rating and $110 target, citing strong growth potential from AI-powered oncology testing and genomic profiling services.